ROLE OF URSODEOXYCHOLIC ACID IN ENHANCEMENT THE RESPONSE TO ALPHA INTERFERONE IN TREATMENT OF CHRONIC HEPATITISC
Dalia Omar Kholosi;
Abstract
The hepatitis C virus (HCV) is the main causative agent ofposttransfusion hepatitis and a common cause of sporadic hepatitis. It leads ultimately to cirrhosis in I 0% to 25% of infected patients. Recombinant alfa interferon (aiFN) is the base treatment of chronic hepatitis C, but its efficacy remains rather unsatisfactory (Alter, et al.,
1995).
Therefore, there is a crucial need to evaluate therapeutic protocols combining IFN with other putatively active drugs. One oftl;lese drugs could be the ursodeoxycholic acid (UDCA) as UDCA is a safe and well-tolerated anticholestatic drug that has been reported to be effective in decreasing serum alanine transaminase
(ALT) levels, not only in patients with chronic
choIestat1.c
64 159
1seases, m patient
s W•ith
ch rom.e
hepat1.t1.s
whether or not related to virus infection (De Caestecker, eta!., 1991).
1995).
Therefore, there is a crucial need to evaluate therapeutic protocols combining IFN with other putatively active drugs. One oftl;lese drugs could be the ursodeoxycholic acid (UDCA) as UDCA is a safe and well-tolerated anticholestatic drug that has been reported to be effective in decreasing serum alanine transaminase
(ALT) levels, not only in patients with chronic
choIestat1.c
64 159
1seases, m patient
s W•ith
ch rom.e
hepat1.t1.s
whether or not related to virus infection (De Caestecker, eta!., 1991).
Other data
| Title | ROLE OF URSODEOXYCHOLIC ACID IN ENHANCEMENT THE RESPONSE TO ALPHA INTERFERONE IN TREATMENT OF CHRONIC HEPATITISC | Other Titles | دور حامض ارسوديسوكسى كوليك فى زيادة فاعلية عقار الانترفيرون فى علاج الالتهاب الكبدى الفيروسى (سى) | Authors | Dalia Omar Kholosi | Issue Date | 2001 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.